Clinical activity of idelalisib (GS-1101), a selective inhibitor of PI3Kδ, in phase 1 and 2 trials in chronic lymphocytic leukemia (CLL): Effect of del(17p)/TP53 mutation, del(11q), IGHV mutation, and NOTCH1 mutation Meeting Abstract

  

Authors:	Coutre, S. E.; Leonard, J. P.; Barrientos, J. C.; De Vos, S.; Flinn, I.; Furman, R. R.; Brown, J. R.; Wagner-Johnston, N.; Benson, D. M. Jr; Schreeder, M. T.; Sharman, J. P.; Boyd, T.; Spurgeon, S.; Zelenetz, A. D.; Lamanna, N.; Kipps, T. J.; Kahl, B. S.; Bello, C. M.; Burger, J. A.; Rai, K. R.; Dansey, R.; Kim, Y.; Holes, L. M.; Lazarov, M.; Dubowy, R. L.; O'Brien, S. M.
Abstract Title:	Clinical activity of idelalisib (GS-1101), a selective inhibitor of PI3Kδ, in phase 1 and 2 trials in chronic lymphocytic leukemia (CLL): Effect of del(17p)/TP53 mutation, del(11q), IGHV mutation, and NOTCH1 mutation
Meeting Title:	55th Annual Meeting of the American Society of Hematology (ASH)
Journal Title:	Blood
Volume:	122
Issue:	21
Meeting Dates:	2013 Dec 7-10
Meeting Location:	New Orleans, LA
ISSN:	0006-4971
Publisher:	American Society of Hematology
Date Published:	2013-11-15
Language:	English
ACCESSION:	WOS:000331385003269
PROVIDER:	wos
DOI:	10.1182/blood.V122.21.1632.1632
Notes:	Meeting Abstract: 1632 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/125667